Comparison between drug-eluting bead transarterial chemoembolization versus conventional TACE in elderly patients with colorectal cancer liver metastases: a cohort study - Takeaways - MDSpire

Comparison between drug-eluting bead transarterial chemoembolization versus conventional TACE in elderly patients with colorectal cancer liver metastases: a cohort study

  • By

  • Liying Tian

  • Bao Hu

  • Meifang Song

  • Yunpeng Li

  • Fan Yang

  • Jiecheng Yang

  • June 10, 2026

  • 0 min

Share

  • 1

    DEB-TACE offers higher intratumor drug concentration and lower systemic toxicity compared to conventional TACE in elderly patients with CRCLM.

  • 2

    In a cohort of 43 elderly patients, DEB-TACE showed a longer median progression-free survival than cTACE, with 11.7 months versus 6.1 months.

  • 3

    The complete response rate for DEB-TACE was 10.0%, while cTACE had a rate of 4.3%, although these differences were not statistically significant.

  • 4

    Overall survival showed a tendency to improve with DEB-TACE (21.6 months) compared to cTACE (16.3 months), but this was not statistically significant.

  • 5

    Adverse events were similar between DEB-TACE and cTACE, including fever, pain, and blood count changes, indicating comparable safety profiles.

Original Source(s)

Comparison between drug-eluting bead transarterial chemoembolization versus conventional TACE in elderly patients with colorectal cancer liver metastases: a cohort study

  • by Liying Tian, Bao Hu, Meifang Song, Yunpeng Li, Fan Yang, Jiecheng Yang

  • June 10, 2026

Related Content

Clinical-scale 10-day TCR-T cell manufacturing using IL-2/7/15 and TGF-β promotes early memory and tissue-resident-like phenotypes and robust antitumor activity in vitro

Identification, design, and in vivo proof of concept of a shared APC neoantigen delivered via a self-amplifying RNA containing virus-like nanoparticle for cancer vaccination

A study on risk prediction of decline in self-care ability one month after discharge in postoperative colorectal cancer patients based on routine clinical indicators